Payment overview · 2025
General Payments
$268.87
8 reported records · 6 companies
Healthcare provider profile · identity verified
Patrick Timothy Bringardner, FNP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · COOS BAY, OR · NPI 1154877025
Verified facts
What the public records show
CMS Open Payments records show Patrick Timothy Bringardner, FNP-BC received $268.87 in general payments during 2025 across 8 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 39.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $106.25 | 39.5% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $46.42 | 17.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.74 | 12.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.33 | 12.4% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $29.50 | 11.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.63 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $252.88 | 7 |
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $106.25 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $46.42 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $33.33 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $29.50 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 262 | 72 |
| Losartan Potassium | Losartan Potassium | 236 | 62 |
| Omeprazole | Omeprazole | 196 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 194 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 162 | 42 |
| Lisinopril | Lisinopril | 137 | 35 |
| Gabapentin | Gabapentin | 124 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 46 |
| Furosemide | Furosemide | 101 | 26 |
| Metformin Hcl | Metformin Hcl | 101 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 27 |
| Trazodone Hcl | Trazodone Hcl | 78 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 73 | 20 |
| Estradiol | Estradiol | 72 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 19 |
| Potassium Chloride | Potassium Chloride | 67 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 57 | 18 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 57 | 43 |
| Simvastatin | Simvastatin | 57 | 16 |
| Carvedilol | Carvedilol | 56 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 54 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 53 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 11 |
| Sertraline Hcl | Sertraline Hcl | 51 | 13 |
| Metformin Hcl Er | Metformin Hcl | 50 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 46 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 45 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 45 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | suppressed |
| Jardiance | Empagliflozin | 42 | 12 |
| Famotidine | Famotidine | 40 | 11 |
| Lovastatin | Lovastatin | 40 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 14 |
| Eliquis | Apixaban | 38 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 11 |
| Meloxicam | Meloxicam | 37 | 12 |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 37 | suppressed |
| Allopurinol | Allopurinol | 36 | 11 |
| Spironolactone | Spironolactone | 36 | 11 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Unifine Ultra Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 13 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $268.87 · 8 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, BREZTRI, GVOKE HYPOPEN, JOURNAVX, REXULTI, The Cologuard Plus Collection Kit, ZENPEP | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error